Micvotabart Pelidotin (MICVO) – An Innovative Extracellular-Targeting ADC Rapidly Through Clinical Developement
- An extracellular ADC intentionally designed against a novel and specifically expressed noncellular cancer target, EDB+FN
- Ph1 Clinical data demonstrate PoC for MICVO's novel extracellular mechanism with favorable safety, PK, tolerability and early efficacy profile
- Initial development focus in R/M HNSCC with expansion potential into multiple solid tumors